BID "Ellison Adds Two Clinical Development Experts... Accelerating Oncology Clinical Trials"

[Asia Economy Reporter Hyunseok Yoo] VIDI announced on the 19th that its U.S. subsidiary Ellison Pharmaceuticals has newly appointed Matt Cromie as Vice President and Clinical Development Supervisor, and Michael Rusty as Vice President and head of CMC (Chemistry, Manufacturing and Control). This is expected to accelerate clinical trials for the oncology pipeline currently underway at Ellison.

Vice President Matt Cromie holds a master's degree in Science and Medical Informatics from Michigan Technology University and Northwestern University. He is a veteran clinical development supervisor with top-level experience managing clinical operations over the past eight years at pharmaceutical companies such as Henrui Therapeutics and Raphael.

Vice President Michael Rusty has been working in the bio industry for 10 years and holds a Ph.D. from Ulster University in Philadelphia. He has served as a CMC lead at various companies ranging from startups to Fortune 500 companies, and as a product development leader for FDA approvals and first product launches. He is expected to become a key member of Ellison.

The Clinical Development Supervisor is responsible for overseeing the entire new drug development process through clinical trials, including large-scale manufacturing process development of candidate substances, formulation research, safety evaluation, and in vivo pharmacokinetics. CMC refers to documenting and verifying research and development related to the quality of raw materials and finished pharmaceuticals, as well as consistency control and management of manufacturing processes during drug development.

A VIDI official stated, “By recruiting top-level experts in clinical development and CMC respectively, Ellison’s ongoing clinical trials for oncology pipelines can proceed more systematically and efficiently, and be managed with standardized documentation.”

He added, “To enable Ellison to successfully conduct clinical trials and facilitate rapid decision-making and close consultation with major shareholders, we are considering directly registering VIDI CEO Seungman Ahn as an executive of Ellison by August.”

Meanwhile, Ellison is conducting FDA Phase 3 clinical trials for the pancreatic cancer treatment ‘Glufosphamide.’ The lung cancer treatment ILC received approval for Phase 2 clinical trials from China’s National Medical Products Administration (NMPA) in December last year. It recently obtained FDA approval for Phase 2/3 clinical trial plans. With improvements in raw material supply, the prototype product of ILC is expected to be launched in the fourth quarter of this year.